LEGEND BIOTECH CORPORA

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

12 11 2024 06:00:01 提供 Nasdaq GlobeNewswire

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

07 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

05 11 2024 08:10:00 提供 Nasdaq GlobeNewswire

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

04 11 2024 06:30:00 提供 Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

24 10 2024 07:00:01 提供 Nasdaq GlobeNewswire

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

03 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

27 9 2024 15:35:00 提供 Nasdaq GlobeNewswire

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

20 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

09 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

08 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

26 7 2024 06:00:00 提供 Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

10 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

02 7 2024 07:00:00 提供 Nasdaq GlobeNewswire